当前位置: X-MOL 学术Expert Rev. Vaccines › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT
Expert Review of Vaccines ( IF 6.2 ) Pub Date : 2021-09-01 , DOI: 10.1080/14760584.2021.1964962
Federico Martinón-Torres 1, 2 , Isabelle Bertrand-Gerentes 3 , Philipp Oster 3
Affiliation  

ABSTRACT

Introduction

Although quadrivalent meningococcal conjugate vaccines have been effective in preventing invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y across age groups from infants to adults, data on their efficacy and safety in adults ≥56 years of age are lacking. Moreover, multiple available quadrivalent conjugate vaccines require reconstitution prior to administration, introducing the potential for error. A novel quadrivalent meningococcal conjugate vaccine, MenACYW-TT (MenQuadfi®) was approved in 2020 for use in individuals ≥12 months of age as a single dose in the European Union and some other countries and in individuals ≥2 years of age in the United States.

Areas covered

The findings of Phase II/III studies that included >6600 individuals and evaluated the immunogenicity and safety of MenACYW-TT beyond the first year of life are comprehensively summarized and discussed.

Expert opinion

Extensive data on immunogenicity and safety, co-administration with routine vaccines, elicitation of robust booster responses, and significantly higher Men C responses versus monovalent MenC or MenACWY standard-of-care vaccines in toddlers suggest that MenACYW-TT may be suitable for inclusion in National Immunization Programs (NIPs) globally. The authors provide their perspectives on the clinical use of MenACYW-TT across age groups from toddlers through adults.



中文翻译:

一种预防出生后第一年脑膜炎球菌疾病的新型疫苗:MenACYW-TT 的早期回顾

摘要

介绍

尽管四价脑膜炎球菌结合疫苗在预防从婴儿到成人的各个年龄组的 A、C、W 和 Y 血清群引起的侵袭性脑膜炎球菌病 (IMD) 方面都有效,但缺乏关于其在 56 岁以上成人中的有效性和安全性的数据. 此外,多种可用的四价结合疫苗需要在给药前进行重组,这可能会导致错误。一种新型的四价脑膜炎球菌结合疫苗 MenACYW-TT (MenQuadfi®) 于 2020 年在欧盟和其他一些国家被批准用于 ≥12 个月大的个体,在欧盟和其他一些国家和≥2 岁的个体中使用状态。

涵盖的领域

对超过 6600 名个体的 II/III 期研究结果进行了全面总结和讨论,该研究评估了 MenACYW-TT 在生命第一年之后的免疫原性和安全性。

专家意见

关于免疫原性和安全性、与常规疫苗共同给药、引发强烈的加强反应以及在幼儿中与单价 MenC 或 MenACWY 标准护理疫苗相比 Men C 反应显着更高的大量数据表明,MenACYW-TT 可能适合纳入全球国家免疫计划 (NIP)。作者提供了他们对 MenACYW-TT 跨年龄组从幼儿到成人的临床使用的看法。

更新日期:2021-09-12
down
wechat
bug